BeiGene (BGNE)
(Delayed Data from NSDQ)
$206.82 USD
+4.09 (2.02%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $206.96 +0.14 (0.07%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
BGNE 206.82 +4.09(2.02%)
Will BGNE be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for BGNE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BGNE
Waters Stock Gains on Earnings & Sales Beat in Q3, Raised View
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
BGNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last?
Wall Street Analysts See a 27.84% Upside in BeiGene (BGNE): Can the Stock Really Move This High?
Other News for BGNE
BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion
BeiGene to share new Brukinsa data at ASH Annual Meeting
BeiGene to share new Brukinsa data at ASH Annual Meeting
Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab
Indaptus Therapeutics signs clinical supply agreement with Beigene